Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the COVID-19 Drug Associated APIs Market Growth Performance Trended Historically, And What Lies Ahead?

There has been significant growth in the market size for APIs associated with COVID-19 drugs in the past few years. The market is anticipated to expand from $6.75 billion in 2024 to $7.14 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.8%. This historical growth is credited to the increased occurrence of COVID-19 cases, heightened awareness about treatment options for the disease, broadening accessibility to these drugs, heightened demand for COVID-19 prophylaxis drugs, government schemes, and a resilient supply chain.

What Is the Forecast for the COVID-19 Drug Associated APIs Market Size Through 2029?

A substantial surge is forecasted in the market size of APIs associated with COVID-19 drugs in the coming years, with an expected growth to $9.08 billion by 2029, indicating a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period can be linked to the emergence of new COVID-19 drug modalities, the escalation in clinical trials for drugs related to COVID-19, an increasing demand for vaccines against COVID-19, the emergence of new variants, ongoing vaccination campaigns, and enhanced readiness for pandemics. The key trends expected in the forecast period encompass tailored production of APIs, diversification of API sources, advancements in manufacturing technologies, data analytics and digitalization, as well as sustainability and environmentally friendly chemistry.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp

What are the Key Market Players in COVID-19 Drug Associated APIs Market and How They’re Evolving?

Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy’s Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.

What Are the Primary Growth Drivers in the COVID-19 Drug Associated APIs Market?

The active pharmaceutical ingredients (APIs) market is experiencing increased demand due to the need for antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory medications used in the production of COVID-19 drugs. These APIs are the critical biological components utilized in the creation of pharmaceutical drugs. Currently, Remdesivir and Favipiravir are commonly used antiviral medications in dealing with COVID-19 patients. While Remdesivir has received emergency use authorization in the USA and Japan for treating COVID-19 patients, the FDA has approved Airsupra (albuterol and budesonide), an inhalation aerosol. Airsupra is used as and when needed for the treatment or prevention of bronchoconstriction and lowering the risk of asthma attacks in patients aged 18 and above. Favipiravir, typically used to treat influenza in Japan, has shown favorable results on COVID-19 patients. Given that COVID-19 is a respiratory disease, the need for bronchodilators has noticeably risen. The growing demand for antivirals, antimalarials, and bronchodilators is expected to drive the growth of the APIs market related to COVID-19 drug production in the projected period.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3248&type=smp

What Are the Leading Segments in the Global COVID-19 Drug Associated APIs Industry?

The COVID-19 drug associated apis market covered in this report is segmented –

1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class

2) By Synthesis Type: Synthetic, Biotech

3) By Business Mode: Captive API, Merchant API

Subsegments:

1) By Antimalarials: Hydroxychloroquine, Chloroquine

2) By Bronchodilators: Beta-Agonists, Anticholinergics

3) By Antibiotics: Macrolides, Tetracyclines

4) By Antivirals: Remdesivir, Favipiravir, Lopinavir Or Ritonavir

5) By Other Drug Classes: Corticosteroids, Immunomodulators

What Are the Key Market Trends in the COVID-19 Drug Associated APIs Industry?

Prominent entities in the pharmaceutical sector making APIs related to COVID-19 drugs are concentrating on plans such as enhancing plant or production capacity to cater to the surging demand owing to the escalating count of COVID-19 cases worldwide. For instance, Merck & Co., Inc., a pharmaceutical organization based in the US, in October 2023, in collaboration with India’s Heavy Water Board, aspires to penetrate the deuterated raw compound market, currently valued at about $100 million and potentially escalating to $1 billion within the upcoming five to ten years. Merck’s aim is to assist the chemical, pharmaceutical, and technical segments of India by supplying superior-quality compounds for the production of medicines, semiconductors, OLEDs, and electronics. Currently, Avigan’s effectiveness and safety for treating COVID-19 patients are being examined in clinical trials.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report

What Is the Regional Outlook for the COVID-19 Drug Associated APIs Market?

The countries covered in the COVID-19 drug associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3248

This Report Delivers Insight On:

1. How big is the covid-19 drug associated apis market, and how is it changing globally?

2. Who are the major companies in the covid-19 drug associated apis market, and how are they performing?

3. What are the key opportunities and risks in the covid-19 drug associated apis market right now?

4. Which products or customer segments are growing the most in the covid-19 drug associated apis market?

5. What factors are helping or slowing down the growth of the covid-19 drug associated apis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model